Sight Sciences (SGHT)
(Delayed Data from NSDQ)
$5.10 USD
-0.04 (-0.78%)
Updated Apr 26, 2024 09:41 AM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
SGHT 5.10 -0.04(-0.78%)
Will SGHT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SGHT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGHT
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
Sight Sciences (SGHT) to Expand in Europe With New Launch
SGHT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
Other News for SGHT
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNIĀ® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Sight Sciences (SGHT)
Sight Sciences publishes results from MIGS study in AJO
Fly Intel: Pre-Market Movers